Amendment #2 to the Cooperative Research and Development Agreement, dated February 1, 2019, by and among the National Cancer Institute, Ziopharm Oncology, Inc. and Precigen, Inc

Pursuant to that certain Exclusive License Agreement by and between Ziopharm Oncology, Inc., Precigen, Inc., and Intrexon Corporation, dated October 5, 2018, Precigen, Inc. has agreed to assign to Ziopharm Oncology Inc. all of Precigen Inc.’s rights, titles and interests in the CRADA. Thus, Precigen, Inc. hereby assigns all of its rights, titles, interests and benefits in and to CRADA #03111 to Ziopharm Oncology, Inc. In addition, Precigen, Inc. hereby assigns, and Ziopharm Oncology, Inc. hereby assumes, all of Precigen Inc.’s responsibilities under CRADA #03111 accruing on or after October 5, 2018. For clarity, Ziopharm Oncology, Inc. and NCI shall release Precigen, Inc. from all duties, claims, obligations and liabilities under CRADA #03111 upon execution of this amendment.

Precigen, Inc. is removed as a Collaborator, and Ziopharm Oncology, Inc is now the only Collaborator. All references in the CRADA to Collaborator and Precigen, Inc. shall be deemed to refer to Ziopharm Oncology, Inc. The definition of “Collaborator” is modified as follows: “Collaborator” means Ziopharm Oncology, Inc. as the context dictates, collectively, Intrexon and ZIOPHARM, or individually Intrexon or ZIOPHARM.

Upon final signature, the term of the CRADA is extended for two (2) years from January 9, 2020 to January 9, 2022.

The CRADA title is modified to read as follows: “Development and Evaluation of Precigen Inc.’s Ziopharm Oncology, Inc.’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification of Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods”.

The CRADA abstract is modified to read as follows: Under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI), Precigen, Inc. and Ziopharm Oncology, Inc. will develop and evaluate adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the isolation of tumor-reactive T Cell Receptors (TCRs) targeting unique, patient specific mutated neoantigen(s) and introduction of said TCRs into T cell subsets isolated from peripheral blood using Precigen, Inc. Ziopharm Oncology, Inc. Non-Viral Sleeping Beauty Transposon and Transposases for the treatment of patients with solid tumor malignancies.

The Contacts Information Page is deleted in its entirety and replaced with the Contacts Information Page in Exhibit 1.

/s/ James H. Doroshow, M.D.

/s/ Donald P. Lehr

/s/ Kevin Lafond

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]